EXITED
COMPANY NAME

HistoRX

INDUSTRY

Healthcare IT - Diagnostics

LOCATIONS

New Haven, CT

EXITED

Novartis (Genoptix)

HistoRx built predictive companion diagnostic tests that rapidly identify, validate and spatially map proteomic biomarkers, and diseases in tissue samples.

BUILDING A MARKET LEADER

Brook was the lead investor in HistoRx and helped build a business around commercializing a technology originally developed at Yale Medical School. Brook helped the business grow its technology portfolio and revenue base, and managed the M&A process leading to the Company’s purchase by Genoptix, a division of Novartis, in 2012. The business’ novel biomarkers continue to help today’s physicians diagnose and create better care regimens, primarily in the oncology market.